Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1

Conditions

Wilms Tumor 1Multiple Myeloma 1

Interventions

sargramostim 2liposomal amphotericin B 2Voriconazole 2Therapeutics 2Polymerase Chain Reaction 2Itraconazole 2Flow Cytometry 2Amplified Fragment Length Polymorphism Analysis 2thymoglobulin 1aldesleukin 1Valacyclovir 1Stem Cell Transplantation 1Rituximab 1Ribavirin 1Radiotherapy 1Proteasome Inhibitors 1Prednisone 1Peripheral Blood Stem Cell Transplantation 1Pentetic Acid 1Palivizumab 1Monatide (IMS 3015) 1Minocycline 1Methylprednisolone 1Methotrexate 1Lithium Carbonate 1Lithium 1Lenalidomide 1Interleukin-12 Subunit p35 1Interferon-alpha 1Immunomodulating Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Wilms Tumor × Immunomodulating Agents × Plasma cell × Clear all
NCT01827137 2024-09-19

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

Sellas Life Sciences Group

Phase 1/2 Completed
20 enrolled 9 charts
GenitourinaryPlasma cell

Multiple Myeloma, Wilms Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡